JP2014533275A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014533275A5 JP2014533275A5 JP2014541293A JP2014541293A JP2014533275A5 JP 2014533275 A5 JP2014533275 A5 JP 2014533275A5 JP 2014541293 A JP2014541293 A JP 2014541293A JP 2014541293 A JP2014541293 A JP 2014541293A JP 2014533275 A5 JP2014533275 A5 JP 2014533275A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- group
- glycoloyl
- tetradecahydro
- phenanthren
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 15
- 210000001508 eye Anatomy 0.000 claims description 11
- 206010065062 Meibomian gland dysfunction Diseases 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 5
- 206010013774 Dry eye Diseases 0.000 claims description 5
- 208000010217 blepharitis Diseases 0.000 claims description 5
- 210000005252 bulbus oculi Anatomy 0.000 claims description 5
- 210000000795 conjunctiva Anatomy 0.000 claims description 5
- 201000004700 rosacea Diseases 0.000 claims description 5
- 206010010741 Conjunctivitis Diseases 0.000 claims description 4
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 4
- 208000028006 Corneal injury Diseases 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 208000001344 Macular Edema Diseases 0.000 claims description 4
- 206010025415 Macular oedema Diseases 0.000 claims description 4
- 206010037508 Punctate keratitis Diseases 0.000 claims description 4
- 206010038848 Retinal detachment Diseases 0.000 claims description 4
- 206010046851 Uveitis Diseases 0.000 claims description 4
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 4
- 230000007815 allergy Effects 0.000 claims description 4
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 4
- 210000004087 cornea Anatomy 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000002458 infectious effect Effects 0.000 claims description 4
- 230000009545 invasion Effects 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 201000010230 macular retinal edema Diseases 0.000 claims description 4
- 230000002980 postoperative effect Effects 0.000 claims description 4
- 230000005855 radiation Effects 0.000 claims description 4
- 230000004264 retinal detachment Effects 0.000 claims description 4
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 206010072139 Ocular rosacea Diseases 0.000 claims description 3
- 206010030865 Ophthalmic herpes zoster Diseases 0.000 claims description 3
- 210000000744 eyelid Anatomy 0.000 claims description 3
- 239000003862 glucocorticoid Substances 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 230000004410 intraocular pressure Effects 0.000 claims description 3
- 201000004614 iritis Diseases 0.000 claims description 3
- 230000007170 pathology Effects 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 241001303601 Rosacea Species 0.000 claims description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 10
- 239000000872 buffer Substances 0.000 claims 10
- 239000008213 purified water Substances 0.000 claims 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- 239000008363 phosphate buffer Substances 0.000 claims 5
- 239000001103 potassium chloride Substances 0.000 claims 5
- 235000011164 potassium chloride Nutrition 0.000 claims 5
- 239000011780 sodium chloride Substances 0.000 claims 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 4
- 229920001983 poloxamer Polymers 0.000 claims 4
- 229960000502 poloxamer Drugs 0.000 claims 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 4
- 229940069328 povidone Drugs 0.000 claims 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- 239000008351 acetate buffer Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 235000011187 glycerol Nutrition 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- 239000007981 phosphate-citrate buffer Substances 0.000 claims 3
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 2
- 229960004926 chlorobutanol Drugs 0.000 claims 2
- 239000007979 citrate buffer Substances 0.000 claims 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims 2
- 239000007951 isotonicity adjuster Substances 0.000 claims 2
- 229940096826 phenylmercuric acetate Drugs 0.000 claims 2
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 claims 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims 2
- 229940033663 thimerosal Drugs 0.000 claims 2
- 239000012929 tonicity agent Substances 0.000 claims 2
- 102000003676 Glucocorticoid Receptors Human genes 0.000 claims 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims 1
- 102100021316 Mineralocorticoid receptor Human genes 0.000 claims 1
- 210000004240 ciliary body Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 235000002639 sodium chloride Nutrition 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 3
- 230000001886 ciliary effect Effects 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161558775P | 2011-11-11 | 2011-11-11 | |
| US61/558,775 | 2011-11-11 | ||
| PCT/US2012/064296 WO2013071010A1 (en) | 2011-11-11 | 2012-11-09 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF 4-PREGENEN-11ß-17-21-TRIOL-3,20-DIONE DERIVATIVES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014533275A JP2014533275A (ja) | 2014-12-11 |
| JP2014533275A5 true JP2014533275A5 (https=) | 2016-07-28 |
| JP6158201B2 JP6158201B2 (ja) | 2017-07-05 |
Family
ID=47179019
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541292A Expired - Fee Related JP6216719B2 (ja) | 2011-11-11 | 2012-11-09 | 眼病態の治療のための４−プレゲネン−１１ｓｓ−１７−２１−トリオール−３，２０−ジオン誘導体 |
| JP2014541293A Expired - Fee Related JP6158201B2 (ja) | 2011-11-11 | 2012-11-09 | ４−プレゲネン−１１β−１７−２１−トリオール−３，２０−ジオン誘導体の医薬組成物および使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541292A Expired - Fee Related JP6216719B2 (ja) | 2011-11-11 | 2012-11-09 | 眼病態の治療のための４−プレゲネン−１１ｓｓ−１７−２１−トリオール−３，２０−ジオン誘導体 |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US8906892B2 (https=) |
| EP (2) | EP2776041A1 (https=) |
| JP (2) | JP6216719B2 (https=) |
| KR (2) | KR20140095549A (https=) |
| CN (2) | CN104185472B (https=) |
| AR (1) | AR088846A1 (https=) |
| AU (3) | AU2012335590B2 (https=) |
| BR (2) | BR112014011333B1 (https=) |
| CA (3) | CA2855290C (https=) |
| CL (2) | CL2014001243A1 (https=) |
| CO (2) | CO6970598A2 (https=) |
| ES (1) | ES2806603T3 (https=) |
| HK (1) | HK1200366A1 (https=) |
| IL (2) | IL232534A0 (https=) |
| IN (2) | IN2014CN03903A (https=) |
| MX (3) | MX365859B (https=) |
| MY (2) | MY172227A (https=) |
| PH (2) | PH12014501079B1 (https=) |
| RU (2) | RU2688159C2 (https=) |
| SG (3) | SG10201603766PA (https=) |
| TW (1) | TWI584809B (https=) |
| UA (2) | UA116622C2 (https=) |
| WO (2) | WO2013071010A1 (https=) |
| ZA (2) | ZA201403431B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| UA116622C2 (uk) | 2011-11-11 | 2018-04-25 | Аллерган, Інк. | Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей |
| ES2750523T3 (es) | 2012-12-18 | 2020-03-26 | Almirall Sa | Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3 |
| TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽 |
| TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有ｍａｂａ化合物和皮質類固醇之組合 |
| AU2014361790B2 (en) * | 2013-12-13 | 2019-05-23 | Allergan, Inc. | Polymorphic and amorphous forms of cortisol 17-alpha-benzoate and methods for the preparation and use thereof |
| TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物 |
| KR20170120161A (ko) * | 2015-03-05 | 2017-10-30 | 알러간, 인코포레이티드 | 안과용 약물 전달을 위한 자가-유화 약물 전달 시스템(sedds) |
| CA3037176A1 (en) * | 2016-09-16 | 2018-03-22 | Kala Pharmaceuticals, Inc. | Particles, compositions, and methods for ophthalmic and/or other applications |
| WO2019055028A1 (en) * | 2017-09-15 | 2019-03-21 | Kala Pharmaceuticals, Inc. | PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC APPLICATIONS AND / OR OTHER APPLICATIONS |
| CN116023425B (zh) * | 2023-03-28 | 2023-06-20 | 南京师范大学 | 曲安西龙衍生物及其医药用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL6605514A (https=) * | 1966-04-25 | 1967-10-26 | ||
| IT1056711B (it) * | 1967-04-01 | 1982-02-20 | Vismara F Spa | Derivati dell idrocortisone |
| US3484436A (en) * | 1967-09-07 | 1969-12-16 | Syntex Corp | Bicyclo(2.2.2)octane - 1 - -carboxylate esters of delta**4 - pregnene corticoid steroids |
| GB1227992A (https=) | 1968-01-23 | 1971-04-15 | Koninklijke Gist Spiritus | |
| US3693032A (en) | 1971-04-23 | 1972-09-19 | Ibm | Antisaturation technique for ttl circuits |
| US3984544A (en) * | 1975-02-28 | 1976-10-05 | Schering Corporation | Retinoic acid esters of steroids of the pregnane series, their use in the treatment of acne and pharmaceutical formulations useful therefor |
| JPS52136157A (en) * | 1976-04-14 | 1977-11-14 | Taisho Pharmaceut Co Ltd | Preparation of steroid 17-esters |
| JPS60994B2 (ja) * | 1976-07-26 | 1985-01-11 | 大正製薬株式会社 | プレグナン系化合物の１７α―エステル類の製造法 |
| DE2735110A1 (de) * | 1977-08-04 | 1979-02-15 | Hoechst Ag | Corticoid-17-alkylcarbonate und verfahren zu ihrer herstellung |
| US4221787A (en) * | 1978-03-28 | 1980-09-09 | Interx Research Corporation | Esteramide prodrugs of anti-inflammatory corticosteroids |
| US4221778A (en) * | 1979-01-08 | 1980-09-09 | Pennwalt Corporation | Prolonged release pharmaceutical preparations |
| DE4025342A1 (de) * | 1990-08-10 | 1992-02-13 | Hoechst Ag | In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel |
| US6011023A (en) * | 1997-08-27 | 2000-01-04 | Alcon Laboratories, Inc. | Angiostatic steroids |
| ATE241640T1 (de) * | 1999-10-15 | 2003-06-15 | Leo Pharm Prod Ltd | Fusidinsäure-derivate |
| US6395721B1 (en) | 2000-01-05 | 2002-05-28 | Leonard Bloom | Low potency unpreserved sterile topical corticosteroid compositions for dermatitis |
| EA011095B1 (ru) * | 2002-08-29 | 2008-12-30 | Бёрингер Ингельхайм Фармасьютиклз, Инк. | Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний |
| JP2005008596A (ja) * | 2003-06-20 | 2005-01-13 | Kobayashi Pharmaceut Co Ltd | 眼科用組成物 |
| SI1755616T1 (sl) * | 2004-04-08 | 2014-04-30 | Eye Co Pty Ltd. | Zdravljenje eksudativne retinopatije z mineralkortikoidi |
| CA2573668A1 (en) * | 2004-07-12 | 2006-02-16 | Allergan, Inc. | Ophthalmic compositions and methods for treating ophthalmic conditions |
| US7691811B2 (en) * | 2006-05-25 | 2010-04-06 | Bodor Nicholas S | Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye |
| US7687484B2 (en) * | 2006-05-25 | 2010-03-30 | Bodor Nicholas S | Transporter enhanced corticosteroid activity |
| PL1864668T3 (pl) * | 2006-06-01 | 2013-04-30 | Santen Sas | Wykorzystanie proleku do okulistycznego podawania śródszklistkowego |
| ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
| JP2009053880A (ja) | 2007-08-27 | 2009-03-12 | Sony Broadband Solution Corp | 情報処理装置、ならびにｃｐｕユニット |
| CA2710149A1 (en) * | 2007-12-21 | 2009-07-09 | John C. Anthes | C20-c21 substituted glucocorticoid receptor agonists |
| MX379265B (es) * | 2008-06-26 | 2025-03-11 | Anterios Inc | Aplicacion dérmica de toxina botulínica en nanoemulsiones para usarse en el tratamiento de trastornos de la piel. |
| UA116622C2 (uk) * | 2011-11-11 | 2018-04-25 | Аллерган, Інк. | Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей |
-
2012
- 2012-09-11 UA UAA201406244A patent/UA116622C2/uk unknown
- 2012-09-11 UA UAA201406457A patent/UA111867C2/uk unknown
- 2012-11-09 IN IN3903CHN2014 patent/IN2014CN03903A/en unknown
- 2012-11-09 SG SG10201603766PA patent/SG10201603766PA/en unknown
- 2012-11-09 CN CN201280066021.2A patent/CN104185472B/zh not_active Expired - Fee Related
- 2012-11-09 IN IN3919CHN2014 patent/IN2014CN03919A/en unknown
- 2012-11-09 BR BR112014011333A patent/BR112014011333B1/pt not_active IP Right Cessation
- 2012-11-09 MX MX2014005679A patent/MX365859B/es active IP Right Grant
- 2012-11-09 WO PCT/US2012/064296 patent/WO2013071010A1/en not_active Ceased
- 2012-11-09 EP EP12787337.0A patent/EP2776041A1/en not_active Withdrawn
- 2012-11-09 RU RU2014123472A patent/RU2688159C2/ru not_active IP Right Cessation
- 2012-11-09 AU AU2012335590A patent/AU2012335590B2/en not_active Ceased
- 2012-11-09 TW TW101141986A patent/TWI584809B/zh not_active IP Right Cessation
- 2012-11-09 MY MYPI2014001373A patent/MY172227A/en unknown
- 2012-11-09 CA CA2855290A patent/CA2855290C/en not_active Expired - Fee Related
- 2012-11-09 EP EP12787336.2A patent/EP2776040B1/en active Active
- 2012-11-09 KR KR1020147015650A patent/KR20140095549A/ko not_active Abandoned
- 2012-11-09 US US13/673,623 patent/US8906892B2/en not_active Expired - Fee Related
- 2012-11-09 RU RU2014123471A patent/RU2683775C2/ru not_active IP Right Cessation
- 2012-11-09 SG SG11201402225RA patent/SG11201402225RA/en unknown
- 2012-11-09 CA CA2855929A patent/CA2855929C/en not_active Expired - Fee Related
- 2012-11-09 BR BR112014011341A patent/BR112014011341A2/pt not_active Application Discontinuation
- 2012-11-09 HK HK15101080.2A patent/HK1200366A1/xx unknown
- 2012-11-09 JP JP2014541292A patent/JP6216719B2/ja not_active Expired - Fee Related
- 2012-11-09 AU AU2012335589A patent/AU2012335589B2/en not_active Ceased
- 2012-11-09 MY MYPI2014001372A patent/MY182222A/en unknown
- 2012-11-09 CA CA2991883A patent/CA2991883C/en not_active Expired - Fee Related
- 2012-11-09 KR KR1020147015647A patent/KR102049615B1/ko not_active Expired - Fee Related
- 2012-11-09 ES ES12787336T patent/ES2806603T3/es active Active
- 2012-11-09 SG SG11201402247PA patent/SG11201402247PA/en unknown
- 2012-11-09 JP JP2014541293A patent/JP6158201B2/ja not_active Expired - Fee Related
- 2012-11-09 MX MX2014005678A patent/MX363669B/es unknown
- 2012-11-09 WO PCT/US2012/064293 patent/WO2013071009A1/en not_active Ceased
- 2012-11-09 CN CN201280065948.4A patent/CN104203247B/zh not_active Expired - Fee Related
- 2012-11-09 US US13/673,074 patent/US8865691B2/en not_active Expired - Fee Related
- 2012-11-12 AR ARP120104261A patent/AR088846A1/es unknown
-
2014
- 2014-05-09 PH PH12014501079A patent/PH12014501079B1/en unknown
- 2014-05-09 MX MX2019006877A patent/MX2019006877A/es unknown
- 2014-05-09 PH PH12014501078A patent/PH12014501078B1/en unknown
- 2014-05-11 IL IL232534A patent/IL232534A0/en active IP Right Grant
- 2014-05-11 IL IL232535A patent/IL232535B/en active IP Right Grant
- 2014-05-12 CL CL2014001243A patent/CL2014001243A1/es unknown
- 2014-05-12 CL CL2014001244A patent/CL2014001244A1/es unknown
- 2014-05-13 ZA ZA2014/03431A patent/ZA201403431B/en unknown
- 2014-05-13 ZA ZA2014/03430A patent/ZA201403430B/en unknown
- 2014-05-29 CO CO14116546A patent/CO6970598A2/es unknown
- 2014-06-09 CO CO14124183A patent/CO6970609A2/es unknown
- 2014-09-12 US US14/485,335 patent/US9717743B2/en not_active Expired - Fee Related
- 2014-11-05 US US14/533,847 patent/US9433631B2/en not_active Expired - Fee Related
-
2016
- 2016-08-04 US US15/228,674 patent/US10493082B2/en not_active Expired - Fee Related
-
2017
- 2017-06-30 US US15/640,093 patent/US10188667B2/en not_active Expired - Fee Related
-
2018
- 2018-01-19 AU AU2018200436A patent/AU2018200436B2/en not_active Ceased
- 2018-12-24 US US16/231,901 patent/US20190365786A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014533275A5 (https=) | ||
| CN104185472B (zh) | 4‑孕甾烯‑11β‑17‑21‑三醇‑3，20‑二酮衍生物的药物组合物和使用方法 | |
| AU2011284589B2 (en) | Compounds for the treatment/prevention of ocular inflammatory diseases | |
| JP2018529693A5 (https=) | ||
| KR101408317B1 (ko) | 후안부 질환 치료를 위한 스테로이드 전구약물의 용도 | |
| CA2603902A1 (en) | Ophthalmic formulations and uses thereof | |
| AR095073A1 (es) | Compuesto híbrido con una porción ciclosporina a y una porción de esteroide, uso de dicho compuesto para preparar una composición farmacéutica tópica y dicha composición | |
| ES2911174T3 (es) | Soluciones de bimatoprost y timolol sin conservantes | |
| JP2021515777A (ja) | 眼科用製剤 | |
| CN101842080A (zh) | 非水的水混溶性物质作为药物递送的载体 | |
| US20250195489A1 (en) | Methods of treating ocular inflammatory diseases | |
| JP2024056898A (ja) | 眼周囲分泌腺におけるまたは眼表面での異常な炎症を処置するための組成物および使用方法 | |
| JP2020533270A5 (https=) | ||
| JP2013537551A5 (https=) | ||
| JP2024506384A (ja) | ロフルミラストの眼科的送達方法 | |
| CA2808628A1 (en) | Ophthalmic formulations of squalamine | |
| CN101284006A (zh) | 一种治疗眼部疾病的药物组合物 | |
| DK3229780T3 (en) | Ophthalmic composition for use in the treatment of dry eye syndrome | |
| Mithal et al. | Difluprednate: an overview | |
| Patel et al. | Difluprednate in ophthalmic practice | |
| RU2633055C1 (ru) | Офтальмологическая композиция для лечения конъюнктивитов, блефаритов и краевой язвы роговицы при местном применении | |
| US20250032468A1 (en) | Ocular surface topical administration of roflumilast for treatment of anterior and retinal-vitreous chamber ocular diseases | |
| Karaca et al. | Complication Management in Adenoviral Keratoconjunctivitis | |
| HK40113755A (zh) | 治疗眼部炎性疾病的方法 | |
| CN121263183A (zh) | 吡美莫司用于治疗患者的特征在于牛津分级量表角膜染色评分为4或5分的干眼症的用途 |